Exousia Bio (LMMY) Cash from Financing Activities (2022 - 2025)

Exousia Bio has disclosed Cash from Financing Activities across 4 years of filings, most recently posting $21.9 million for Q4 2025.

• Cash from Financing Activities for Q4 2025 came in at $21.9 million, up 25380.85% year-over-year; the trailing twelve-month figure through Nov 2025 was $22.0 million (up 26338.61% YoY), and the FY2025 annual result was $3500.0, down 38.13% from the prior year.
• Cash from Financing Activities came in at $21.9 million for Q4 2025 at Exousia Bio, up from -$3500.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $21.9 million in Q4 2025 to a low of -$86538.0 in Q4 2024.
• The 4-year median for Cash from Financing Activities is $1416.0 (2024), against an average of $1.7 million.
• Across the five-year window, Cash from Financing Activities sank 6220.08% in 2024 and jumped 25380.85% in 2025, its largest moves.
• Exousia Bio's Cash from Financing Activities stood at $4296.0 in 2022, then tumbled by 67.09% to $1414.0 in 2023, then tumbled by 6220.08% to -$86538.0 in 2024, then surged by 25380.85% to $21.9 million in 2025.
• The last three Cash from Financing Activities figures came in at $21.9 million (Q4 2025), -$3500.0 (Q3 2025), and $3500.0 (Q2 2025), per Business Quant data.